让癌症不再是绝症，癌细胞“狙击手”十年长跑

Core Viewpoint - The article highlights the advancements and potential of CAR-T cell therapy developed by Yimiao Shenzhou, a private unicorn company in Beijing, which aims to revolutionize the treatment of late-stage cancers, particularly colorectal cancer and lymphoma, through innovative approaches in immunotherapy [5][11][12]. Company Overview - Yimiao Shenzhou was founded in 2015 by a team of Tsinghua University graduates, including CEO He Ting, with the mission to develop CAR-T therapies for cancer patients in China [7][13]. - The company has made significant progress in its research pipeline, with CAR-T therapies for lymphoma and colorectal cancer expected to be approved for market within the next few years [5][11]. Technology and Innovation - CAR-T therapy utilizes the patient's own T cells, which are genetically modified to target and destroy cancer cells, representing a shift towards personalized medicine [5][11]. - The company has developed several proprietary technologies, including serum-free suspension lentivirus production and efficient T cell activation techniques, positioning itself as a leader in the domestic biopharmaceutical industry [16]. Market Context - The article emphasizes the growing importance of the biopharmaceutical sector in Beijing, which is projected to reach a total scale of 1.06 trillion yuan by 2024, making it the first city in China to surpass the trillion-yuan mark in this industry [16]. - China's position in the global gene and cell therapy market is strengthening, with the country now ranking among the top two in terms of clinical trial numbers and patient treatments [12][16]. Future Outlook - The next decade is seen as crucial for domestic CAR-T technology to break the overseas monopoly, with expectations for a "domestic first" era in the biopharmaceutical field [12][16]. - The supportive policies and market dynamics in Beijing are expected to foster the emergence of more unicorn companies in the healthcare sector [16].